Eli Lilly and Company - Cogs Excluding Depreciation and Amortization

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Cogs-Excluding-Depreciation-and-Amortization" stands at 8.19 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.

Eli Lilly and Company's third quarter result of 2.54 Billion USD for the item "Cogs Excluding Depreciation and Amortization" represents an increase of 28.89 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 2.54 Billion USD for the item "Cogs Excluding Depreciation and Amortization" represents an increase of 48.96 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 8.19 Billion USD for the item "Cogs Excluding Depreciation and Amortization" represents an increase of 11.35 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 33.51 percent compared to the value the year prior.
The 1 year change in percent is 33.51.
The 3 year change in percent is 47.83.
The 5 year change in percent is 118.40.
The 10 year change in percent is 135.46.

The Serie's long term average value is 4.45 Billion United States Dollars. It's latest available value, on 09/30/2025, is 84.09 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2013, to it's latest available value, on 09/30/2025, is +148.19%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.